A patient on insulin glargine asks why it cannot be mixed with short-acting insulin in the same syringe. The pharmacological reason is:

• A Glargine competes with short-acting insulin at insulin receptor binding sites
• B Glargine contains zinc that forms insoluble complexes with all other insulins
• C Glargine requires co-administration with protamine which inactivates short-acting insulin
• D Glargine's pH 4 formulation precipitates neutral-pH short-acting insulins, altering absorption kinetics of both ✓

Explanation

Insulin glargine is formulated at pH 4 (acidic) to maintain solubility. When injected subcutaneously into the physiological pH 7.4 environment, it forms microprecipitates that dissolve slowly, providing a flat, 24-hour basal profile without a pronounced peak. Mixing glargine with neutral-pH insulins (regular, aspart, lispro) results in partial neutralization of glargine's acidic pH, causing it to precipitate in the vial and unpredictably altering the absorption profile of both insulins. For this reason, glargine must always be injected separately. Protamine is used in NPH insulin, not glargine.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.